CEVA or SNPS: Which Semiconductor Stock Is Worth Buying Now?

Zacks favors Synopsys over CEVA, citing its AI-driven EDA momentum, 82% recurring revenue mix, and fiscal Q3 2026 EDA revenue growth of 8.5% year over year. Synopsys raised fiscal 2026 operating cash-flow guidance to about $2.8 billion and free-cash-flow guidance to about $2.6 billion, while holding $3.61 billion of cash and short-term investments. CEVA's licensing revenue rose 21% to $18.2 million in Q2 2026, but Synopsys' stronger earnings-surprise record, operational performance, and relative share performance support its Zacks Rank #2 Buy rating versus CEVA's #3 Hold.

Analysis

The relevant distinction is not AI exposure but monetization timing. SNPS sells mission-critical workflow software into customers' R&D budgets, so rising design complexity can convert into recurring-seat, verification-capacity and services spend before a chip ships. CEVA's economics are more convex but delayed: license wins are low-visibility indicators until licensees reach production, leaving royalties exposed to handset, IoT and automotive unit cycles. This favors SNPS in a cautious semiconductor spending environment, while CEVA needs evidence of royalty conversion rather than additional contract announcements.

SNPS's broader platform creates a second-order competitive issue for point IP vendors: AI-assisted design makes interoperability across EDA, verification and IP more valuable, potentially raising switching costs and increasing share of wallet for SNPS and Cadence (CDNS). The counterpoint is that heightened workload intensity may increase compute requirements faster than customers accept higher EDA pricing, limiting near-term margin leverage. The key 1-3 month catalyst is whether management translates AI engagement activity into backlog, renewal pricing and FY27 growth commentary; generic AI claims are already well understood and should not command incremental multiple expansion alone.

Contrarian view: CEVA's lower sales multiple is not automatically a bargain because revenue composition matters materially; a small licensing base can produce volatile quarterly comparisons and royalties are both delayed and concentrated. However, its depressed share price may create asymmetric upside over 6-18 months if OEM-direct agreements produce disclosed production ramps, particularly in automotive connectivity and edge processing. QBTS has no operational read-through from either company's design-IP momentum and should not be used as an AI basket proxy; its valuation is driven by quantum adoption and financing risk, not semiconductor design-cycle demand.

Key Decisions for Investors

• Maintain a 3-6 month long SNPS / short CEVA pair, sized beta-neutral: favor the earlier, recurring monetization model over back-end royalty optionality. Reassess if CEVA discloses a material production royalty ramp or if SNPS guides EDA growth below high-single digits.
• For a less idiosyncratic expression, own SNPS versus CDNS only after relative underperformance of at least 5%; both benefit from design complexity, but SNPS needs demonstrable cross-sell and pricing realization to close any valuation discount. Avoid chasing on an analyst-rating-driven open.
• Treat CEVA as a watch-list event trade rather than a core long. Initiate only following independently measurable evidence of royalty-bearing chips entering volume production or sustained royalty growth; the upside case is a rerating toward larger IP peers, while failure to convert licenses leaves downside tied to weak end-device demand.
• Do not infer a signal for QBTS from this news. Maintain any QBTS exposure separately against quantum-specific milestones, cash burn and capital-raise risk.